Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials

Xinfang Xie, Youxia Liu, Vlado Perkovic, Xiangling Li, Toshiharu Ninomiya, Wanyin Hou, Na Zhao, Lijun Liu, Jicheng Lv, Hong Zhang, Haiyan Wang

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background There is much uncertainty regarding the relative effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in populations with chronic kidney disease (CKD). Study Design Systematic review and Bayesian network meta-analysis. Setting & Population Patients with CKD treated with renin-angiotensin system (RAS) inhibitors. Selection Criteria for Studies Randomized trials in patients with CKD treated with RAS inhibitors. Predictor ACE inhibitors and ARBs compared to each other and to placebo and active controls. Outcome Primary outcome was kidney failure; secondary outcomes were major cardiovascular events, all-cause death. Results 119 randomized controlled trials (n = 64,768) were included. ACE inhibitors and ARBs reduced the odds of kidney failure by 39% and 30% (ORs of 0.61 [95% credible interval, 0.47-0.79] and 0.70 [95% credible interval, 0.52-0.89]), respectively, compared to placebo, and by 35% and 25% (ORs of 0.65 [95% credible interval, 0.51-0.80] and 0.75 [95% credible interval, 0.54-0.97]), respectively, compared with other active controls, whereas other active controls did not show evidence of a significant effect on kidney failure. Both ACE inhibitors and ARBs produced odds reductions for major cardiovascular events (ORs of 0.82 [95% credible interval, 0.71-0.92] and 0.76 [95% credible interval, 0.62-0.89], respectively) versus placebo. Comparisons did not show significant effects on risk for cardiovascular death. ACE inhibitors but not ARBs significantly reduced the odds of all-cause death versus active controls (OR, 0.72; 95% credible interval, 0.53-0.92). Compared with ARBs, ACE inhibitors were consistently associated with higher probabilities of reducing kidney failure, cardiovascular death, or all-cause death. Limitations Trials with RAS inhibitor therapy were included; trials with direct comparisons of other active controls with placebo were not included. Conclusions Use of ACE inhibitors or ARBs in people with CKD reduces the risk for kidney failure and cardiovascular events. ACE inhibitors also reduced the risk for all-cause mortality and were possibly superior to ARBs for kidney failure, cardiovascular death, and all-cause mortality in patients with CKD, suggesting that they could be the first choice for treatment in this population.

Original languageEnglish
Pages (from-to)728-741
Number of pages14
JournalAmerican Journal of Kidney Diseases
Volume67
Issue number5
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Angiotensin Receptor Antagonists
Renin-Angiotensin System
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Randomized Controlled Trials
Renal Insufficiency
Kidney
Cause of Death
Placebos
Population
Mortality
Network Meta-Analysis
Patient Selection
Uncertainty
Therapeutics

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD : A Bayesian Network Meta-analysis of Randomized Clinical Trials. / Xie, Xinfang; Liu, Youxia; Perkovic, Vlado; Li, Xiangling; Ninomiya, Toshiharu; Hou, Wanyin; Zhao, Na; Liu, Lijun; Lv, Jicheng; Zhang, Hong; Wang, Haiyan.

In: American Journal of Kidney Diseases, Vol. 67, No. 5, 01.05.2016, p. 728-741.

Research output: Contribution to journalArticle

Xie, Xinfang ; Liu, Youxia ; Perkovic, Vlado ; Li, Xiangling ; Ninomiya, Toshiharu ; Hou, Wanyin ; Zhao, Na ; Liu, Lijun ; Lv, Jicheng ; Zhang, Hong ; Wang, Haiyan. / Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD : A Bayesian Network Meta-analysis of Randomized Clinical Trials. In: American Journal of Kidney Diseases. 2016 ; Vol. 67, No. 5. pp. 728-741.
@article{c06515508f5e427f800b2681b1dbf4a9,
title = "Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials",
abstract = "Background There is much uncertainty regarding the relative effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in populations with chronic kidney disease (CKD). Study Design Systematic review and Bayesian network meta-analysis. Setting & Population Patients with CKD treated with renin-angiotensin system (RAS) inhibitors. Selection Criteria for Studies Randomized trials in patients with CKD treated with RAS inhibitors. Predictor ACE inhibitors and ARBs compared to each other and to placebo and active controls. Outcome Primary outcome was kidney failure; secondary outcomes were major cardiovascular events, all-cause death. Results 119 randomized controlled trials (n = 64,768) were included. ACE inhibitors and ARBs reduced the odds of kidney failure by 39{\%} and 30{\%} (ORs of 0.61 [95{\%} credible interval, 0.47-0.79] and 0.70 [95{\%} credible interval, 0.52-0.89]), respectively, compared to placebo, and by 35{\%} and 25{\%} (ORs of 0.65 [95{\%} credible interval, 0.51-0.80] and 0.75 [95{\%} credible interval, 0.54-0.97]), respectively, compared with other active controls, whereas other active controls did not show evidence of a significant effect on kidney failure. Both ACE inhibitors and ARBs produced odds reductions for major cardiovascular events (ORs of 0.82 [95{\%} credible interval, 0.71-0.92] and 0.76 [95{\%} credible interval, 0.62-0.89], respectively) versus placebo. Comparisons did not show significant effects on risk for cardiovascular death. ACE inhibitors but not ARBs significantly reduced the odds of all-cause death versus active controls (OR, 0.72; 95{\%} credible interval, 0.53-0.92). Compared with ARBs, ACE inhibitors were consistently associated with higher probabilities of reducing kidney failure, cardiovascular death, or all-cause death. Limitations Trials with RAS inhibitor therapy were included; trials with direct comparisons of other active controls with placebo were not included. Conclusions Use of ACE inhibitors or ARBs in people with CKD reduces the risk for kidney failure and cardiovascular events. ACE inhibitors also reduced the risk for all-cause mortality and were possibly superior to ARBs for kidney failure, cardiovascular death, and all-cause mortality in patients with CKD, suggesting that they could be the first choice for treatment in this population.",
author = "Xinfang Xie and Youxia Liu and Vlado Perkovic and Xiangling Li and Toshiharu Ninomiya and Wanyin Hou and Na Zhao and Lijun Liu and Jicheng Lv and Hong Zhang and Haiyan Wang",
year = "2016",
month = "5",
day = "1",
doi = "10.1053/j.ajkd.2015.10.011",
language = "English",
volume = "67",
pages = "728--741",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD

T2 - A Bayesian Network Meta-analysis of Randomized Clinical Trials

AU - Xie, Xinfang

AU - Liu, Youxia

AU - Perkovic, Vlado

AU - Li, Xiangling

AU - Ninomiya, Toshiharu

AU - Hou, Wanyin

AU - Zhao, Na

AU - Liu, Lijun

AU - Lv, Jicheng

AU - Zhang, Hong

AU - Wang, Haiyan

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background There is much uncertainty regarding the relative effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in populations with chronic kidney disease (CKD). Study Design Systematic review and Bayesian network meta-analysis. Setting & Population Patients with CKD treated with renin-angiotensin system (RAS) inhibitors. Selection Criteria for Studies Randomized trials in patients with CKD treated with RAS inhibitors. Predictor ACE inhibitors and ARBs compared to each other and to placebo and active controls. Outcome Primary outcome was kidney failure; secondary outcomes were major cardiovascular events, all-cause death. Results 119 randomized controlled trials (n = 64,768) were included. ACE inhibitors and ARBs reduced the odds of kidney failure by 39% and 30% (ORs of 0.61 [95% credible interval, 0.47-0.79] and 0.70 [95% credible interval, 0.52-0.89]), respectively, compared to placebo, and by 35% and 25% (ORs of 0.65 [95% credible interval, 0.51-0.80] and 0.75 [95% credible interval, 0.54-0.97]), respectively, compared with other active controls, whereas other active controls did not show evidence of a significant effect on kidney failure. Both ACE inhibitors and ARBs produced odds reductions for major cardiovascular events (ORs of 0.82 [95% credible interval, 0.71-0.92] and 0.76 [95% credible interval, 0.62-0.89], respectively) versus placebo. Comparisons did not show significant effects on risk for cardiovascular death. ACE inhibitors but not ARBs significantly reduced the odds of all-cause death versus active controls (OR, 0.72; 95% credible interval, 0.53-0.92). Compared with ARBs, ACE inhibitors were consistently associated with higher probabilities of reducing kidney failure, cardiovascular death, or all-cause death. Limitations Trials with RAS inhibitor therapy were included; trials with direct comparisons of other active controls with placebo were not included. Conclusions Use of ACE inhibitors or ARBs in people with CKD reduces the risk for kidney failure and cardiovascular events. ACE inhibitors also reduced the risk for all-cause mortality and were possibly superior to ARBs for kidney failure, cardiovascular death, and all-cause mortality in patients with CKD, suggesting that they could be the first choice for treatment in this population.

AB - Background There is much uncertainty regarding the relative effects of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in populations with chronic kidney disease (CKD). Study Design Systematic review and Bayesian network meta-analysis. Setting & Population Patients with CKD treated with renin-angiotensin system (RAS) inhibitors. Selection Criteria for Studies Randomized trials in patients with CKD treated with RAS inhibitors. Predictor ACE inhibitors and ARBs compared to each other and to placebo and active controls. Outcome Primary outcome was kidney failure; secondary outcomes were major cardiovascular events, all-cause death. Results 119 randomized controlled trials (n = 64,768) were included. ACE inhibitors and ARBs reduced the odds of kidney failure by 39% and 30% (ORs of 0.61 [95% credible interval, 0.47-0.79] and 0.70 [95% credible interval, 0.52-0.89]), respectively, compared to placebo, and by 35% and 25% (ORs of 0.65 [95% credible interval, 0.51-0.80] and 0.75 [95% credible interval, 0.54-0.97]), respectively, compared with other active controls, whereas other active controls did not show evidence of a significant effect on kidney failure. Both ACE inhibitors and ARBs produced odds reductions for major cardiovascular events (ORs of 0.82 [95% credible interval, 0.71-0.92] and 0.76 [95% credible interval, 0.62-0.89], respectively) versus placebo. Comparisons did not show significant effects on risk for cardiovascular death. ACE inhibitors but not ARBs significantly reduced the odds of all-cause death versus active controls (OR, 0.72; 95% credible interval, 0.53-0.92). Compared with ARBs, ACE inhibitors were consistently associated with higher probabilities of reducing kidney failure, cardiovascular death, or all-cause death. Limitations Trials with RAS inhibitor therapy were included; trials with direct comparisons of other active controls with placebo were not included. Conclusions Use of ACE inhibitors or ARBs in people with CKD reduces the risk for kidney failure and cardiovascular events. ACE inhibitors also reduced the risk for all-cause mortality and were possibly superior to ARBs for kidney failure, cardiovascular death, and all-cause mortality in patients with CKD, suggesting that they could be the first choice for treatment in this population.

UR - http://www.scopus.com/inward/record.url?scp=84948823375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948823375&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2015.10.011

DO - 10.1053/j.ajkd.2015.10.011

M3 - Article

C2 - 26597926

AN - SCOPUS:84948823375

VL - 67

SP - 728

EP - 741

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -